CONTENTS:
- Effects of cannabis use on neurocognition: A scoping review of MRI studies. Audi D., Hajeer S., Saab M.B., Saab L., Harati H., Desoutter A., et al., p. 357-373.
- Significant psychedelic experiences evaluated for mystical characteristics associated with cannabis use reduction and psychological flexibility improvement: A naturalistic cross-sectional retrospective survey. Romeo B., Kervadec E., Fauvel B., Strika-Bruneau L., Amirouche A., Verroust V., et al., p. 374-385.
- Pharmacokinetics of psilocybin, a tryptamine alkaloid in magic mushroom (Psilocybe cubensis): A systematic review. Thaoboonruang N., Lohitnavy M., Lohitnavy O., p. 386-398.
- The epidemiology of psychedelic use among United States military veterans. Davis A.K., Bates M., Lund E.M., Sepeda N.D., Levin A.W., Armstrong S.B., et al., p. 399-412.
- Personal psychedelic experience as a training qualification for facilitators: A thematic analysis of qualitative interviews with psilocybin experts. Wilson-Poe A., Hoffman K., Pertl K., Luoma J., Bazinet A., Stauffer C., et al., p. 413-420.
- Magic of the mushrooms: Effects of psilocybin decriminalization. Bhave A., p. 421-430.
- A cross-sectional survey investigating M?ori and non-M?ori cancer patients' views on psychedelic-assisted therapy in Aotearoa New Zealand. Best G., Morunga E., Wells A., Allison J., Reynolds L., p. 431-443.
- Factors associated with an increased risk of opioid misuse among patients with non-cancer pain in Malaysian pain clinic settings. Sani A.R., Zin C.S., p. 444-454.
- Correlates of current methamphetamine use and opioid co-use among Latina women in a low-income community. Frankeberger J., Perdue T., Ramirez E., Valdez A., Cepeda A., p. 455-464.
- Ethical issues in treating substance use disorders: Counselor perspectives. Sorensen J.L., McCuistian C., Fokuo J.K., Del Pino H.E., Smith J.D., Elahi S., et al., p. 465-474.